Skip to content

Psilocybin research published in 2021

Page 3 of 9: studies 41 to 60 of 177, newest first. Back to the psilocybin overview

Studies

Psilocybin: Next to treat depression, OCD and nicotine addiction

Alcoholism & Drug Abuse Weekly September 24, 2021 Alison Knopf

First it was the plant, cannabis. How could this be made into a saleable profit‐making commodity when it grows in the ground? Witness the marijuana (a chemical from the plant) industry, which lobbied to make sure laws in states that legalized it banned people from growing more than a few plants.

A whole genome atlas of 81 Psilocybe genomes as a resource for psilocybin production.

F1000Research September 23, 2021 Kevin Mckernan, Liam T. Kane, Yvonne Helbert et al. 10 citations

The Psilocybe genus is well known for the synthesis of valuable psychoactive compounds such as Psilocybin, Psilocin, Baeocystin and Aeruginascin. The ubiquity of Psilocybin synthesis in Psilocybe has been attributed to a horizontal gene transfer mechanism of a ~20Kb gene cassette. A recently published highly contiguous reference genome derived from long read single molecule sequencing has...

Evaluating the risk of psilocybin for the treatment of bipolar depression: A review of the research literature and published case studies

Journal of Affective Disorders Reports September 22, 2021 David E. Gard, Mollie Pleet, Ellen Bradley et al. 33 citations

Growing evidence suggests that psilocybin, the active ingredient in hallucinogenic mushrooms, can rapidly and durably improve symptoms of depression, leading to recent breakthrough status designation by the FDA and legalization for mental health treatment in some jurisdictions. Depression in bipolar disorder is associated with significant morbidity and has few effective treatments. However,...

DOI: 10.1016/j.jadr.2021.100240 (opens in new tab) Full text (opens in new tab) Psilocybin Depression economics Bipolar disorder Psychotherapist +3

Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis.

Journal of Affective Disorders September 17, 2021 Nannan Li, Yi-Ru Hu, Wang-ni Chen et al.

BACKGROUND Previous studies have shown that psilocybin has antidepressant effects. In the current study, we aim to explore the dose effects of psilocybin on primary (major depression patients) and secondary depression (depressed cancer patients). METHODS Published studies concerning psilocybin for depression were retrieved. In accordance with PRISMA guidelines, 6 databases (PubMed, Embase, Web...

New Insights Into the Clinical and Nonclinical Effects of Psychedelic Substances

European Psychologist September 17, 2021 Matthias Forstmann, Christina Sagioglou 6 citations

Abstract. After decades of stagnation, research on psychedelic substances (such as lysergic acid diethylamide [LSD], psilocybin, or N,N-dimethyltryptamine [DMT]) has experienced a renaissance over the last 10 years, with various major research programs being conducted across Europe and the United States. This research primarily investigates the potential of psychedelics in the treatment of...

Neuropsychological Functioning in Users of Serotonergic Psychedelics – A Systematic Review and Meta-Analysis

Frontiers in Pharmacology September 16, 2021 Lukas A Basedow, Thomas Riemer, Simon Reiche et al. 16 citations

Background: Serotonergic psychedelics (SPs) like LSD, psilocybin, DMT, and mescaline are a heterogeneous group of substances that share agonism at 5-HT 2a receptors. Besides the ability of these substances to facilitate profoundly altered states of consciousness, persisting psychological effects have been reported after single administrations, which outlast the acute psychedelic effects. In...

A Qualitative Exploration of Relational Ethical Challenges and Practices in Psychedelic Healing

Journal of Humanistic Psychology September 16, 2021 Margo A. Jackson, Joseph G. Ponterotto, Bill Brennan et al. 53 citations

As both 3,4-methylenedioxymethamphetamine (MDMA)- and psilocybin-assisted psychedelic psychotherapy near U.S. Food and Drug Administration (FDA) approval and gain acceptance as efficacious clinical approaches, concerns have been raised about the likelihood of sexual violation of a client and other relational boundary transgressions. In the current study, 23 practitioners who have administered...

DOI: 10.1177/00221678211045265 (opens in new tab) MDMA Psilocybin Competence human resources Psychotherapist +2

Is MDD the right target for early-stage psychedelic-assisted therapy trials?

Journal of Psychedelic Studies September 15, 2021 Benjamin R. Lewis, Kevin Byrne 1 citation

Abstract The recently published Imperial College study of a Phase II, double-blind, randomized, controlled trial comparing psilocybin-assisted therapy to a six-week titration of escitalopram for Major Depressive Disorder (MDD) should raise concerns for this illness category as a target of early psychedelic research given a goal of FDA approval. There are three reasons why MDD is the wrong...

Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis

Journal of Psychopharmacology September 14, 2021 Robert F. Leger, Ellen M. Unterwald 54 citations

Background: Classical psychedelics are a group of drugs which act as agonists on the serotonin-2A (5-HT2A) receptor. Evidence suggests they may have a uniquely rapid and enduring positive effect on mood. However, marked heterogeneity between methodological designs in this emerging field remains a significant concern. Aims: To determine how differences in the type of psychedelic agent used and...

From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders

Journal of Neurochemistry September 14, 2021 Urszula Kozłowska, Charles D. Nichols, Kalina Wiatr et al. 78 citations

Abstract The studies of psychedelics, especially psychedelic tryptamines like psilocybin, are rapidly gaining interest in neuroscience research. Much of this interest stems from recent clinical studies demonstrating that they have a unique ability to improve the debilitating symptoms of major depressive disorder (MDD) long‐term after only a single treatment. Indeed, the Food and Drug...

Psychedelic-Assisted Psychotherapy After COVID-19: The Therapeutic Uses of Psilocybin and MDMA for Pandemic-Related Mental Health Problems

Frontiers in Psychiatry September 6, 2021 Elena Argento, Devon Christie, Lindsay Mackay et al. 12 citations

The COVID-19 pandemic stands to have impacts on mental health and well-being that will extend beyond its formal resolution. Before COVID-19, mental health disorders were already challenging global healthcare systems, directly accounting for 7.4% of the total burden of disease (1, 2). An estimated 1 billion people worldwide suffer from a mental health disorder, with the two most common...

The Role of Psilocybin-Assisted Psychotherapy to Support Patients With Cancer: A Critical Scoping Review of the Research

Journal of Holistic Nursing September 6, 2021 Rebecca H Lehto, Megan Miller, Jessica Sender 16 citations

Treatments for addressing psychiatric mental health issues in vulnerable patients with cancer are established. Yet, many patients persist with unrelenting psychological difficulties despite intervention. There is growing interest in the role of psilocybin-assisted psychotherapy for managing treatment-resistant mental health challenges in patients with cancer. Psilocybin is a naturally occurring...

Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience.

European Neuropsychopharmacology September 1, 2021 Martin K Madsen, Dea S Stenbæk, Albin Arvidsson et al. 132 citations

The emerging novel therapeutic psilocybin produces psychedelic effects via engagement of cerebral serotonergic targets by psilocin (active metabolite). The serotonin 2A receptor critically mediates these effects by altering distributed neural processes that manifest as increased entropy, reduced functional connectivity (FC) within discrete brain networks (i.e., reduced integrity) and increased...

Use of alternative therapy with Psilocybin in oncologic patients with depression and/or anxiety disorders - integrative review

Research, Society and Development August 19, 2021 Frederico Marques Silveira, Amanda Pereira Mendes, Mayara Rodrigues Dos Santos et al. 1 citation

Cancer is not limited to the physical dimension, but it also affects the entire biopsychosocial context in which the patient is inserted, making him more susceptible to psychiatric disorders such as depression and anxiety. These often require pharmacological intervention, and the use of psilocybin, a substance found in mushroom species, is one of the alternatives considered today. The present...

Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review

Pharmaceuticals August 12, 2021 Gniewko Więckiewicz, Iga Stokłosa, Magdalena Piegza et al. 30 citations

Despite many different kinds of substances available for depression treatment, depression itself still appears to be a clinical challenge. Recently, formerly illicit substances came to scientists’ attention, including lysergic acid diethylamide (LSD), psilocybin and dimethyltryptamine (DMT). Some studies suggest that these substances might be effective in depression treatment. The aim of this...

Effects of Ayahuasca on Personality: Results of Two Randomized, Placebo-Controlled Trials in Healthy Volunteers

Frontiers in Psychiatry August 6, 2021 Juliana Mendes Rocha, Giordano Novak Rossi, Flávia de Lima Osório et al. 37 citations

Rationale: Previous studies with the serotonergic hallucinogens LSD and psilocybin showed that these drugs induced changes in personality traits, such as increases in Openness. However, results are inconsistent, and the effects of ayahuasca on personality were never investigated in a controlled trial. Objectives: To assess the effects of ayahuasca on personality in two randomized,...

[Efficacy of psychedelics in psychiatry, a systematic review of the literature].

L'Encephale August 1, 2021 Lucie Berkovitch, Bruno Romeo, Laurent Karila et al. 25 citations

Psychedelics are powerful psychoactive substances. Natural psychedelics have been used for millennia by human civilizations, in particular in Latin America, while synthetic psychedelics were discovered in the 50s, giving rise to a lot of research before they were prohibited. More recently, their therapeutic properties have been studied especially to help patients with psychiatric conditions,...

Pharmacologic Similarities and Differences Among Hallucinogens

The Journal of Clinical Pharmacology August 1, 2021 Kristin Waters 18 citations

Abstract Hallucinogens constitute a unique class of substances that cause changes in the user's thoughts, perceptions, and mood through various mechanisms of action. Although the serotonergic hallucinogens such as lysergic acid diethylamide, psilocybin, and N,N‐ dimethyltryptamine have been termed the classical hallucinogens , many hallucinogens elicit their actions through other mechanisms...

Anti-Inflammatory Effects of Four Psilocybin-Containing Magic Mushroom Water Extracts in vitro on 15-Lipoxygenase Activity and on Lipopolysaccharide-Induced Cyclooxygenase-2 and Inflammatory Cytokines in Human U937 Macrophage Cells

Journal of Inflammation Research August 1, 2021 Sanah Malomile Nkadimeng, Christiaan Ml Steinmann, J.n. Eloff 77 citations

The study suggested that the hot-water extracts of the four psilocybin-containing magic mushrooms have potential anti-inflammatory effects executed by down-regulating pro-inflammatory mediators.

DOI: 10.2147/jir.s317182 (opens in new tab) Lipopolysaccharide U937 cell Cyclooxygenase Inflammation +4